Discovering and developing the next generation of medicines for immune-mediated inflammatory diseases (IMIDs)
NEXT-GENERATION IMID MEDICINES
We’re on a mission to improve the lives of patients with IMIDs.
By focusing on development of first-in-class medicines, we aim to help those IMID patients who fail to respond or develop resistance to current medicines. Furthermore, we intend to develop markers that will help stratify those patients most likely to respond to each of our drugs. Our goal is to deliver the right drug to the right patient.
UNADDRESSED PATIENT NEEDS
IMIDs are a significant lifetime detriment to quality of life for millions
In the US affected by IMIDs
Annual US economic burden from IMIDs
Ulcerative Colitis patients fail to achieve remission
Average time to diagnosis for Systemic Lupus Erythematosus patients
Reduced life expectancy for RA patients
We have created a patient-centric approach to developing IMID medicines
Pipeline of innovative targets derived from proprietary IMID patient data with defined selection criteria
Proprietary, comprehensive clinical, biomolecular data and application of bioinformatics for discovery
Direct ongoing patient access across eight IMIDs, and comprehensive IMID-Biobank
A first-in-class imid pipeline
By focusing on development of first-in-class medicines, we aim to help those IMID patients who fail to respond or develop resistance to current drugs. Furthermore, we intend to develop markers that will help stratify those patients most likely to respond to each of our drugs. Our goal is to deliver the right drug to the right patient.
Data-Driven
Our comprehensive IMID patient data supports target and patient selection
years of data and sample collection
recruiting centers
investigators
Currently targeting eight diseases:
- Systemic Lupus Erythematosus
- Ulcerative Colitis
- Crohn’s Disease
- Rheumatoid Arthritis
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Sjögren’s Syndrome
recruiting centers across spain
IMID patients and control subjects
Clinical variables collected across the eight IMIDs
Clinical and epidemiological data points
Biological specimens (blood and relevant tissues)
COLLABORATING WITH GLOBAL EXPERTS
Key partners and advisors at every stage
“IMIDomics have assembled a unique and world-class platform for clinical and molecular profiling of IMID patients, biobanking and analytics.”
“IMIDomics is uniquely positioned to generate new and important insights that aid in the development of therapeutics to treat IMIDs.”
“It is exciting to be working with IMIDomics to advance the next generation medicines to treat IBD patients. There remains a real need for new treatments for these diseases.”
“To access similar data and capabilities elsewhere would require multiple collaborations with individual clinics, universities, analysis labs, and expert data analytical groups.”
OUR INVESTORS
Backed by industry leaders
Dr. Craves is the Executive Chairman and CEO of IMIDomics and has been involved in the company since it was founded. He was formerly the Founder of Bay City Capital life science investment firm.
As a leader in healthcare venture capital, Dr. Craves brings both scientific skills and deep operational expertise to the companies in which he invests. This allows him to source outstanding investment opportunities and to support exceptional management teams in creating value. He has been associated with some of the most significant exits in the biopharmaceutical industry, including Reliant Pharmaceuticals, a company he founded then sold to GlaxoSmithKline in 2007 in the single largest all-cash transaction for a venture-backed biotech company at that time. Today, Dr. Craves brings decades of experience to the leadership of IMIDomics.
Dr. Craves has been named to the Forbes Midas List, which recognizes the most successful investors in the venture capital asset class across both the technology and healthcare industries. He currently serves on the Boards of IMIDomics, Inc., Madrigal Pharmaceuticals, Synchronicity Pharma and the Gladstone Foundation. Previous investments and board participation, in addition to Reliant Pharmaceuticals, include Medarex, Inc., Incyte Biosciences, Dermira Pharmaceuticals, Twist Bioscience and Ion Torrent. He earned a BS in Biology from Georgetown University and a Ph.D. in Pharmacology and Toxicology from the University of California, San Francisco.